Orion Corp
KRX:271560
Orion Corp
Total Current Liabilities
Orion Corp
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orion Corp
KRX:271560
|
Total Current Liabilities
₩537.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CJ CheilJedang Corp
KRX:097950
|
Total Current Liabilities
₩10T
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Ottogi Corp
KRX:007310
|
Total Current Liabilities
₩1T
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
S
|
Samyang Foods Co Ltd
KRX:003230
|
Total Current Liabilities
₩492.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
|
Dongwon Industries Co Ltd
KRX:006040
|
Total Current Liabilities
₩2.4T
|
CAGR 3-Years
42%
|
CAGR 5-Years
21%
|
CAGR 10-Years
21%
|
|
|
Nongshim Co Ltd
KRX:004370
|
Total Current Liabilities
₩678.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
Orion Corp
Glance View
Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.
See Also
What is Orion Corp's Total Current Liabilities?
Total Current Liabilities
537.6B
KRW
Based on the financial report for Dec 31, 2024, Orion Corp's Total Current Liabilities amounts to 537.6B KRW.
What is Orion Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
3%
Over the last year, the Total Current Liabilities growth was 35%. The average annual Total Current Liabilities growth rates for Orion Corp have been 1% over the past three years , 3% over the past five years .
You don't have any saved screeners yet